An interpretable machine learning model for predicting response to anti-GD2 combined with umbilical cord blood-derived natural killer cell immunotherapy in neuroblastoma.
Source check: Source checked. Not independent scientific confirmation.
Finding: serial peripheral-blood data from 42 patients, dynamic coupling features, seven models with repeated stratified cross-validation; L2 logistic model AUC .873 (bootstrap CI .735–.976), Brier .131. Authors explicitly require larger independent validation.
Technology: Model-enabled response prediction within 42-patient treatment cohort; exploratory cross-validation, not evidence therapy efficacy
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
- AI contribution
- Model-enabled response prediction within 42-patient treatment cohort; exploratory cross-validation, not evidence therapy efficacy.
- Test and result
- serial peripheral-blood data from 42 patients, dynamic coupling features, seven models with repeated stratified cross-validation; L2 logistic model AUC .873 (bootstrap CI .735–.976), Brier .131. Authors explicitly require larger independent validation. Evaluation: Methods/Results: serial peripheral-blood data from 42 patients, dynamic coupling features, seven models with repeated stratified cross-validation; L2 logistic model AUC .873 (bootstrap CI .735–.976), Brier .131.
- Limitation / still unknown
- The 42-patient result is exploratory and internally cross-validated; the authors call for larger independent validation, and treatment benefit was not tested.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2026.1940534/full
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 2/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.